Afya Limited (AFYA)

Executive Summary / Key Takeaways

• Afya has evolved from a medical school consolidator into Brazil's only end-to-end physician ecosystem, achieving record 64.5% gross margins and seven consecutive years of guidance beats, demonstrating that its regulatory moat and operational discipline translate into structurally superior profitability versus diversified education peers.

• The company's capital allocation framework has reached an inflection point, initiating a 40% dividend payout while maintaining M&A discipline and share buybacks, signaling maturity and confidence in predictable cash generation from its 25,556 medical students and 301,000 ecosystem users.

• A strategic pivot in Medical Practice Solutions from freemium user growth to premium monetization has temporarily suppressed MAUs but is building a higher-quality revenue base, with B2B pharmaceutical contracts growing 48% and iClinic penetration accelerating as key data monetization engines.

• Regulatory headwinds including OECD Pillar Two tax implementation (converging to 15% effective rate) and ENAMED quality assessments create near-term margin pressure, but also reinforce Afya's competitive advantage over lower-quality peers who face greater scrutiny and potential seat reductions.

• The cancellation of Mais Médicos III eliminates near-term organic seat expansion, intensifying M&A competition, but benefits incumbents by constraining supply in a market where medical density remains 30% below OECD averages and physician demand grows structurally from Brazil's aging population.

Setting the Scene: Brazil's Medical Education Imperative

Afya Limited, founded in 1999 with the establishment of its first medical school in Brazil and headquartered in Nova Lima, Brazil, operates at the intersection of two powerful secular trends: Brazil's chronic physician shortage and the country's stringent medical education regulation. With approximately 2.98 doctors per 1,000 inhabitants versus Italy's 4.24 and an OECD average that suggests a 30% gap, Brazil faces a structural supply constraint that cannot be solved quickly. The number of physicians has doubled since 2010 to 635,706, yet demand continues to outpace supply, creating a durable tailwind for accredited institutions.

The significance lies in the regulatory moat. Brazil's Ministry of Education (MEC) tightly controls medical school seat approvals through multi-year licensing processes that can cost over R$100 million per campus and take five or more years to complete. Afya's portfolio of 3,755 approved medical seats across 62 campuses represents not just capacity, but a scarce and appreciating asset that competitors cannot easily replicate. This moat translates directly into pricing power: Afya maintains 100% occupancy without discounting even as the candidate-to-seat ratio compressed from 7:1 to 5:1 in 2025, indicating intensifying competition for limited spots.

Afya's positioning versus competitors reveals a critical differentiation. While Yduqs (YDUQY), Cogna (COGN3), Ânima (ANIM3), and Ser Educacional (SEER3) operate diversified education portfolios where medical programs represent a fraction of revenue, Afya generates 85.7% of its undergraduate segment from medicine alone. This focus yields superior margins—64.5% gross margin at the corporate level versus peers struggling in the 20-30% range—but also concentrates risk. The company's end-to-end ecosystem strategy, serving physicians from medical school through residency prep and into clinical practice software, creates network effects that reduce customer acquisition costs to R$1,190 per student while building lifetime value across multiple revenue streams.

Technology, Products, and Strategic Differentiation: The Integrated Ecosystem

Afya's core technological advantage lies not in a single platform but in the integration of three distinct segments into a unified physician lifecycle. The Undergraduate segment provides the foundation with 25,556 medical students generating R$3.26 billion in revenue at 63.9% gross margins. The Continuing Education segment serves these same physicians post-graduation with residency prep and graduate programs, growing revenue 11.4% to R$284.5 million while expanding margins 363 basis points. The Medical Practice Solutions segment completes the circle with clinical decision support and practice management software, reaching 301,000 ecosystem users.

The value of this integration becomes clear when examining the unit economics. Traditional medical schools spend heavily to acquire each new student, but Afya's ecosystem creates a structurally low customer acquisition cost. A medical student using Medcel for residency prep naturally graduates to Whitebook for clinical decision support and iClinic for practice management. This captive audience allows Afya to cross-sell digital solutions with minimal incremental marketing spend, while the data generated across the lifecycle creates a proprietary dataset that pharmaceutical companies will pay to access—evidenced by 48% B2B revenue growth in Continuing Education and 42% B2B growth in Medical Practice Solutions.

The digital transformation currently underway in Medical Practice Solutions illustrates both the opportunity and execution risk. Management implemented a price increase on Whitebook at the end of 2024, deliberately sacrificing freemium users to prioritize premium subscribers. Monthly active users declined from 247,702 in 2023 to 220,051 in 2025, an 11% drop. However, active paying users remained stable at 195,504, and average ticket increased, demonstrating that the user base is becoming more valuable. Afya is transitioning from a volume-based audience model to a monetization-focused platform, which should yield higher lifetime value and more predictable B2B data revenue, but requires execution precision to avoid permanent user churn.

Artificial intelligence integration represents the next layer of differentiation. Afya is embedding AI into iClinic for practice management and Whitebook for clinical decision support, while implementing AI tools in its Shared Services Center to improve operational efficiency. The company can leverage existing content from its residency prep programs and curriculum to prepare for ENAMED exams with marginal CapEx, turning a regulatory requirement into a competitive advantage. This shows how Afya's integrated model allows it to spread development costs across multiple revenue streams, while pure-play education or software competitors must invest separately.

Financial Performance & Segment Dynamics: Evidence of Structural Advantage

Afya's 2025 financial results provide compelling evidence that its strategy is working. Revenue grew 12.4% to R$3.71 billion, with adjusted EBITDA margin reaching a record 45.4%. The company generated R$1.55 billion in operating cash flow at 93.7% conversion, reducing net debt to R$1.34 billion and achieving leverage of just 0.8x EBITDA. These metrics demonstrate that Afya has reached a scale where growth no longer requires proportional capital investment, creating a free cash flow machine that can fund both expansion and shareholder returns.

The segment-level performance reveals the engine driving this profitability. Undergraduate revenue grew 12.4% (9.3% organic) with gross profit up 14.9% to R$2.08 billion. The 63.9% gross margin in Q4 2025 was the result of four factors: the ramp-up of four Mais Médicos campuses launched in Q2 2022, the integration of UNIDOM acquired in July 2024, centralization of academic processes through the Shared Services Center, and disciplined pricing that yielded 2.8% average ticket growth to R$9,060 per student. Margin expansion appears structural, driven by operational leverage and pricing power in a supply-constrained market.

Continuing Education's 11.4% revenue growth and 363 basis point margin expansion to 66.1% gross margin tells a recovery story. The Residency Journey student base declined 21% year-over-year to 12,990 due to a one-time product bundling that eliminated double-counting, but grew 30% sequentially from Q3 2025, indicating the adjustment is complete. More importantly, the Graduate Journey grew 20% to 10,234 students, and B2B revenue surged 48% in Q4. This segment transforms Afya from a one-time education provider into a recurring revenue platform, with graduate programs offering higher margins and longer customer relationships than undergraduate degrees.

Medical Practice Solutions presents a more mixed picture. Revenue grew 5.9% to R$171.3 million, but gross profit declined 2.7% as the segment absorbed investments in product and sales teams. The 11% decline in monthly active users reflects the strategic shift from freemium to premium, while active paying users held steady. Management's review of feature combinations to resume audience growth indicates they recognize the risk of over-optimizing for revenue at the expense of ecosystem scale. Success will be measured by B2B contract growth and iClinic penetration, which provides the data foundation for pharmaceutical monetization.

The balance sheet strength underpins the entire thesis. Afya ended 2025 with R$1.55 billion in cash from operations, used R$1.5 billion in commercial notes to refinance higher-cost debt and repurchase SoftBank's (SFTBY) preferred shares, extending debt maturity to 3.2 years while maintaining cost at 106% of CDI . Net debt declined R$473 million despite funding the FUNIC acquisition and paying dividends. This gives Afya firepower for M&A while returning 40% of net income to shareholders, signaling confidence in intrinsic cash generation capacity.

Outlook, Management Guidance, and Execution Risk

Management's 2026 guidance reveals a deliberate strategic pivot from pure growth to balanced expansion. Revenue is projected at R$3.95-4.10 billion (6-10% growth) with adjusted EBITDA of R$1.70-1.80 billion, implying a 43.5% margin—190 basis points below 2025's 45.4%. This margin compression is a strategic investment choice: the company is accelerating spending in Continuing Education and Medical Practice Solutions to capture faster growth in these higher-margin segments over time. Undergraduate growth is expected in single digits, driven by 5-5.2% tuition increases and modest volume growth as medical programs mature, while the digital segments target double-digit expansion.

This guidance matters because it demonstrates that the core undergraduate business is stable enough to fund investment in ecosystem expansion without sacrificing overall profitability. It also signals a recognition that the next phase of value creation will come from monetizing the 301,000 ecosystem users more effectively. The implied 190 basis point margin decline is the cost of building a more durable, higher-multiple revenue stream.

The ENAMED exam risk requires careful monitoring. Certain Afya programs received a score of 2 (on a 1-5 scale) in the first 2025 cycle, triggering supervisory proceedings. However, management expects no material impact on 2026 guidance because medical school intake occurs in the first half, before the next exam cycle. They are implementing 12 mock test simulations and leveraging existing residency prep assets to prepare for the September 2026 exam, aiming to improve scores for the 2027 intake cycle. While quality compliance is a real operational risk, Afya's integrated curriculum and prep capabilities provide a mitigation pathway.

The OECD Pillar Two tax implementation presents a certain headwind. Brazil's new 15% minimum effective tax rate increased Afya's 2025 provision by R$109.5 million, with management expecting convergence to 15% from 2026 onward. This reduces the value of PROUNI tax benefits that support over 10,000 students across Afya's campuses. Afya must either absorb the cost, pressuring margins by approximately 200-300 basis points, or pass it through via higher tuition, which could test pricing power.

Risks and Asymmetries: What Could Break the Thesis

Three material risks could undermine the investment case. First, the FIES government funding program represents a critical vulnerability. With 17-18% of medical students financed through FIES and a 27.5% retention rate on funds affecting approximately 10 campuses, any reduction in government support would directly impact both enrollment and working capital. If Brazil's fiscal situation forces cuts to education subsidies, Afya's volume growth could stall and margins could compress by 300-400 basis points.

Second, the Medical Practice Solutions transition from freemium to premium carries execution risk. While the strategy prioritizes revenue per user, the 11% decline in monthly active users could become permanent if competitors capture the price-sensitive segment. Failure to re-accelerate user growth would limit the B2B data monetization opportunity that underpins the ecosystem's long-term value. Success could yield 60%+ gross margins, while failure leaves Afya as a traditional education provider with a subscale software business.

Third, the cancellation of Mais Médicos III fundamentally alters the growth algorithm. While constraining supply benefits incumbents, it eliminates Afya's primary organic growth driver of 200+ new seats annually. This forces dependence on M&A, where competition will intensify and valuations may rise. Management's IRR discipline—targeting 200 seats per year only at attractive prices—could result in missed growth if assets become too expensive. Afya's balance sheet strength positions it to win M&A battles, but overpaying for assets would destroy the margin expansion story.

Competitive Context and Positioning

Afya's competitive positioning is best understood through the lens of specialization versus diversification. Against Yduqs (R$5.52 billion revenue, 3.18% growth), Cogna (R$7.02 billion revenue, 9.8% growth), Ânima (R$4.0 billion revenue, 5.8% growth), and Ser Educacional, Afya's R$3.71 billion revenue and 12.4% growth stands out. The key differentiator is margin structure: Afya's 45.4% EBITDA margin compares to peers in the 20-30% range, reflecting the pricing power of medical specialization versus the commoditized non-health programs of diversified players.

Quality metrics further separate Afya from the pack. While 63.3% of Yduqs' medical schools scored 1 or 2 on MEC assessments and Cogna's participating schools scored in the lowest tiers, Afya's average IGC of 2.60 aligns with the national average. ENAMED and future quality assessments will likely penalize low performers with seat reductions, creating a transfer market where Afya's compliant campuses become more valuable.

The ecosystem strategy creates a switching cost that pure education players cannot match. Once a physician trains on Afya's platforms, the data and workflow integration make switching to competitors' software costly. This is evidenced by the 100% occupancy rate and 93.7% cash conversion. Against this, competitors' scale advantages provide cost leverage but not pricing power in the high-margin medical segment where Afya dominates.

Valuation Context

Trading at $14.96 per share with a market capitalization of $1.36 billion, Afya presents a valuation puzzle. The company trades at 9.41x trailing earnings, 1.93x sales, and 5.72x free cash flow, with a 4.39% dividend yield initiated in 2026. These multiples are significantly below U.S. education technology peers but align with Brazilian market risk premiums.

The quality of earnings and cash flow conversion are central to the valuation. Afya's 93.7% cash conversion ratio and 13.3% free cash flow yield demonstrate that reported profits are real and distributable. The 0.8x net debt/EBITDA ratio provides flexibility for M&A or increased shareholder returns. Enterprise value of $1.74 billion at 6.14x EBITDA compares favorably to Cogna's higher leverage and lower margins.

The key valuation driver is whether the market recognizes the ecosystem premium. Traditional education companies trade on enrollment growth and tuition pricing, but Afya's 301,000 ecosystem users and 48% B2B growth suggest a software-like recurring revenue component. The current valuation appears to price Afya as a mature education roll-up rather than an emerging healthcare technology platform. Successful execution on the digital transition could re-rate the stock toward health tech multiples, while failure would leave it as a commoditized education provider.

Conclusion

Afya's investment thesis hinges on the successful evolution from medical education consolidator to integrated physician ecosystem, underpinned by regulatory moats, operational excellence, and disciplined capital allocation. The company's record margins, seven-year guidance streak, and initiation of meaningful dividends demonstrate that the core business generates sustainable cash flows even as it funds digital transformation. The strategic pivot in Medical Practice Solutions from user volume to premium monetization builds a foundation for higher-quality, recurring B2B revenue that leverages Afya's unique physician data.

The critical variables that will determine success are execution on the ENAMED quality improvement plan, which could differentiate Afya from lower-scoring peers, and the pace of ecosystem user re-engagement following the Whitebook pricing reset. If management can resume audience growth while maintaining premium pricing, the B2B pharmaceutical opportunity could drive double-digit segment growth and margin expansion beyond 2026 guidance. Conversely, failure to navigate the FIES/PROUNI tax implications or overpaying for M&A in a post-Mais Médicos III world would compress margins and break the margin expansion narrative.

At current valuations, the market appears to underappreciate both the durability of Afya's regulatory moat and the optionality of its ecosystem strategy. The combination of 45.4% EBITDA margins, 93.7% cash conversion, and a 4.39% dividend yield provides downside protection, while successful digital monetization offers a path to significant re-rating. The story is about leveraging a captive physician audience across the entire professional lifecycle—a transition that transforms Afya from a regional education player into a structural healthcare infrastructure provider.